The complex signaling pathways and interactions inside and among cells which are responsible for the appearance and evolving of malignancy have a distinct and well separated border, the translation process, where the signals of a mutant and dysregulating genome are becoming specific proteins evolving to the malignant phenotype. We selected as translation target the Fragile X -Mental Retardation Protein (FMRP) of the breast cancer cell, a protein of whose role in translation has not clearly elucidated yet. Triple negative breast cancer cell lines (BCCL)-(BT20, MDA-MB-231, Hs578 T) were transfected by plasmid with mutant FMRP at progressively increased CGG triplets (from 45 to 200 repeats at a one by one CGG repeat step up process) and the production of the mutant protein was verified with the SUNSET method and Western blot analysis. Afterwards, the impact in proteinosynthesis inhibition and apoptosis induction of the transfected BCCL in relation to normal epithelial breast cell lines (NEBCL) was evaluated. Preliminary in vitro results showed slower rates of proteinosynthesis and higher apoptotic rate of the 78 CGG & 84 CGG repeat mutant FMRP transfected BCCL in compared to NEBCL, while for all other transfected BCCL no statistically significant differentiation was found.
Introduction
The complex signalling pathways and interactions within and among cells responsible for the appearance and development of malignancy have a distinct and wellseparated border. The border where the "thoughts" -signals of a mutant and dysregulating genome of the cancer cell -take shape to become specific proteins evolving into the malignant phenotype (invasion, stromal dysregulation, immunomodulation and metastasis).
Targeting the beginning (membrane receptors, signalling pathways, second messenger RNAs etc.) or the end (growth factors, MMPs, angiogenetic factors etc.) of this process has not yet led to definitive treatment (with few exceptions).
The new therapeutic target may be the border that the malignant genotype needs to overcome, in order to become a phenotype. This border is the translation process performed within the ribosome, the endoplasmic reticulum and the Golgi apparatus organelles. Targeting the malignant cell at various stages of this process, from the beginning of the formation of the ribosome, through mRNA interaction, until the end of the exit from the Golgi apparatus of the polypeptides responsible for the malignant phenotype may be a novel therapeutic approach against breast cancer research. mutant FMR1 protein (and at which CGS sequencing) by selectively inserting it into the cancer cells (e.g. by using liposome vectors) could be implemented as a novel therapeutic approach. 4. Create transgenic mice groups [5] [7] with agents e.g. micro-organisms formerly used to develop antimicrobial chemotherapeutics targeting the ribosome (e.g. aminoglycosides) and chemically alter the structure of the substance isolated in order to achieve inhibition of cancer cell ribosomes only. 7. Develop a fluorescent agent for breast cancer cell uptake only, thus allowing emitted radiation to be detected and used by a laser machine in a one-by-one cancer cell detection and destruction process for obtaining clear margins, in cases of local advanced disease or thoracic wall recurrence. Note: This protocol was constituted in Athens by Dr. Panagiotis Bouras on 07/03/2016. The above-described methods may be reassessed, modulated, altered or substituted with newly developed techniques or others suggested by fellow scientists participating in the study, and always according to the progress or specific discoveries during the course of this study. The central idea of this study, as described in the introduction and the initial design of methods section, shall irrevocably not alter. The final results of this research study that may be used by pharmaceutical companies or other institutions for further research or medication development for human treatment should always carry the original signature of Dr. Panagiotis Bouras M.D. Ph.D. as seen below:
